Loading organizations...
Based in Cambridge, Massachusetts, Amide Technologies is a biotechnology enterprise that synthesizes complex peptides for commercial biopharmaceutical industry customers using robotic automation and artificial intelligence. The company utilizes rapid flow peptide synthesis technology to provide on demand manufacturing services, effectively shortening drug discovery and production timelines from months to days. This proprietary platform bridges solid phase synthesis and biological expression, enabling the creation of peptide chains that are three times longer than those produced through traditional manufacturing methods. Amide Technologies has raised $16.5 million in total venture capital funding, which includes a recent $7.5 million Series A extension backed by investment firms Engine Ventures, Forcefield Venture Fund, and Biological Engineering Ventures. The organization was originally spun out of the Massachusetts Institute of Technology between 2011 and 2017, and was co-founded by Brad Pentelute, Mark Simon, and Jeremy Wertheimer.
Amide Technologies has raised $15.5M across 2 funding rounds.
Amide Technologies has raised $15.5M in total across 2 funding rounds.
Amide Technologies has raised $15.5M in total across 2 funding rounds.
Amide Technologies's investors include Reed Sturtevant, Forcefield Ventures, Sierra Point Ventures, The Engine.
Amide Technologies has raised $15.5M across 2 funding rounds. Most recently, it raised $7.5M Series A Extension in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2023 | $7.5M Series A Plus | Reed Sturtevant | Forcefield Ventures | Announced |
| Jul 1, 2023 | $8M Series A | — | Sierra Point Ventures, The Engine | Announced |
Amide Technologies is a biotechnology company specializing in on-demand manufacturing of complex peptides that are difficult or impossible to produce via traditional methods.[1][2][4] It serves pharmaceutical and biotech researchers by enabling rapid synthesis of peptides up to 120+ amino acids, including hydrophobic, cyclic, branched, and mirror-image structures, with delivery in as little as four days and a >99% on-time rate, accelerating drug discovery cycles.[1][4][5] Developed at MIT, the company has raised $16.5 million in funding, including a $7.5 million Series A extension in July 2023 led by Engine Ventures, demonstrating strong growth momentum in peptide therapeutics.[1][3]
Amide Technologies originated from MIT labs in 2016, founded by chemistry professor Brad Pentelute and his graduate student Mark Simon, who developed breakthroughs in automated fast-flow peptide synthesis (AFPS) to match ribosomal efficiency.[1][2][5] Their work addressed limitations in solid-phase peptide synthesis (SPPS), enabling rapid production of challenging peptides; early traction came from proving synthesis of complex structures unattainable by cells or standard methods.[2][5] Investor Jeremy Wertheimer, former ITA Software founder and Google VP of Engineering, joined to commercialize the tech, with Mark Simon now CEO and Pentelute leading growth.[1][2]
Amide stands out through its fusion of robotics, AI, and chemistry in AFPS, outperforming traditional SPPS:
Amide rides the peptide therapeutics boom, where peptides offer precise targeting for diseases like cancer and metabolic disorders, fueled by demand for novel modalities beyond antibodies or small molecules.[1][2] Timing aligns with AI-driven drug design and automation in biotech, as flow chemistry scales manufacturing amid biopharma's push for faster iteration—peptides now represent a growing $50B+ market.[1][5] Market forces like supply chain bottlenecks for custom peptides favor Amide, influencing the ecosystem by unlocking "frontier" structures that speed clinical programs and expand therapeutic possibilities.[2][4]
Amide is poised to dominate complex peptide supply as biopharma scales AI-optimized drug discovery, with GMP manufacturing in planning to enter clinical production.[5] Trends like mirror-image proteins for stable therapeutics and robotic synthesis will propel growth, potentially capturing share from legacy vendors. Its influence may evolve from R&D enabler to full-scale CDMO, tying back to its MIT roots in revolutionizing synthesis speed for global drug innovation.[1][5]
